risperidone has been researched along with Agranulocytosis in 14 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine." | 9.12 | Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| "When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine." | 5.12 | Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| " The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)." | 4.80 | Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998) |
| " Surprisingly, there has been little relationship between the pivotal trials designed for FDA approval and current dosing strategies in broader clinical settings." | 2.41 | New antipsychotic medications: more than old wine and new bottles. ( Schulz, SC, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wakuda, T | 1 |
| Suzuki, A | 1 |
| Hasegawa, M | 1 |
| Ichikawa, D | 1 |
| Yamasue, H | 1 |
| McEvoy, JP | 2 |
| Lieberman, JA | 1 |
| Stroup, TS | 1 |
| Davis, SM | 1 |
| Meltzer, HY | 1 |
| Rosenheck, RA | 1 |
| Swartz, MS | 1 |
| Perkins, DO | 1 |
| Keefe, RS | 1 |
| Davis, CE | 1 |
| Severe, J | 1 |
| Hsiao, JK | 1 |
| Kerwin, R | 1 |
| Godleski, LS | 1 |
| Sernyak, MJ | 1 |
| Mahmood, T | 1 |
| Silverstone, T | 1 |
| Finkel, B | 2 |
| Lerner, AG | 1 |
| Oyffe, I | 2 |
| Sigal, M | 2 |
| Lerner, A | 1 |
| Rudinski, D | 1 |
| Weizman, A | 1 |
| Schulz, SC | 1 |
| Zaudig, M | 1 |
| Biswas, A | 1 |
| Mittal, P | 1 |
| Chaturvedi, S | 1 |
| Prasad, A | 1 |
| Hong, X | 1 |
| Wang, X | 1 |
| Allen, TB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| Switching Antipsychotics: Abrupt Discontinuation Versus Overlap[NCT02640300] | Phase 4 | 33 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| Quetiapine in the Treatment of Psychotic Depression - a Pilot Study[NCT00751504] | Phase 3 | 16 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| An Open-Label Trial of Adjunctive Galantamine Maintenance Therapy to Treat Functional Impairments in Chronic Outpatients With Schizophrenia[NCT00232349] | Phase 4 | 21 participants (Actual) | Interventional | 2005-02-28 | Terminated (stopped due to Study terminated due to no apparent benefit.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for risperidone and Agranulocytosis
| Article | Year |
|---|---|
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst | 1998 |
New antipsychotic medications: more than old wine and new bottles.
Topics: Agranulocytosis; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzot | 2000 |
A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia.
Topics: Aged; Aging; Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Humans; Risk A | 2000 |
1 trial available for risperidone and Agranulocytosis
| Article | Year |
|---|---|
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Ove | 2006 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Ove | 2006 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Ove | 2006 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Ove | 2006 |
10 other studies available for risperidone and Agranulocytosis
| Article | Year |
|---|---|
Acute agranulocytosis when switching from risperidone to paliperidone.
Topics: Adolescent; Agranulocytosis; Antipsychotic Agents; Comorbidity; Drug Substitution; Humans; Male; Neu | 2019 |
Adverse reaction reporting and new antipsychotics.
Topics: Agranulocytosis; Anemia, Aplastic; Antipsychotic Agents; Clozapine; Drug Monitoring; Humans; Isoxazo | 1993 |
Agranulocytosis after addition of risperidone to clozapine treatment.
Topics: Adult; Agranulocytosis; Clozapine; Drug Therapy, Combination; Female; Humans; Psychotic Disorders; R | 1996 |
Comments on "Clozapine treatment after agranulocytosis induced by classic neuroleptics".
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Haloperidol; Humans; Male; Risperidone; Schizophrenia; | 1996 |
Risperidone-associated agranulocytosis.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Female; Humans; Risperidone; Schizophrenia, Paranoid | 1998 |
Olanzapine treatment in patients with typical and atypical neuroleptic-associated agranulocytosis.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clopenthixol; Dose-Response Relations | 1998 |
Side Effects of Antipsychotic Medications: Physician's Choice of Medication and Patient Compliance. Dallas, Texas, California. January 22, 1999. Proceedings of a roundtable.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzoth | 2000 |
Risperidone induced cytopenias.
Topics: Aged; Agranulocytosis; Dementia; Female; Follow-Up Studies; Humans; India; Risk Assessment; Risperid | 2000 |
Agranulocytosis and neutropenia with typical and atypical neuroleptics.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Leukocyte | 2001 |
Galantamine for treatment-resistant schizophrenia.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Drug Therapy, Co | 2002 |